Targets › BEST1
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Aug 2030.
Ligand-gated anion channel that allows the movement of anions across cell membranes when activated by calcium (Ca2+). Allows the movement of chloride and hydrogencarbonate. (UniProt, O76090)
Open in Phaseline: the race on BEST1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Opus Genetics | OPGx-BEST1 Gene therapy delivering BEST1 gene via subretinal injection | BEST1 | Phase 1 | ARB | Aug 2030 |
ARB (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.